RMT2 Antibody

What is RMT2 antibody and what is its target?

RMT2 antibodies are a series of monoclonal antibodies that specifically target T-cell immunoglobulin and mucin domain-2 (TIM-2), a transmembrane glycoprotein belonging to the immunoglobulin superfamily. TIM-2 is predominantly expressed on activated lymphocytes and is preferentially upregulated in Th2 cells while being downregulated in Th1 cells. This protein plays a critical role in regulating immune responses, particularly functioning as a negative regulator of Th2 cells, and has been implicated in the development of atopic diseases and other Th2-biased immune responses . TIM-2 also acts as a receptor for Semaphorin 4A, a transmembrane protein expressed on dendritic cells and B cells that enhances T cell activation . Additionally, TIM-2 has been identified as a ligand for H-ferritin, suggesting its involvement in iron metabolism pathways .

What are the main types of RMT2 antibodies available for research?

Three primary RMT2 monoclonal antibody clones have been documented in the literature:

• RMT2-14: A rat IgG2a/λ monoclonal antibody that has been extensively used in studies of TIM-2 function. This is the most widely characterized clone and is commercially available as a recombinant monoclonal antibody .

• RMT2-25: A rat IgG2a/κ monoclonal antibody that has demonstrated somewhat stronger blocking activities than RMT2-14 in experimental settings .

• RMT2-26: A rat IgG2b/κ monoclonal antibody that, similar to RMT2-25, exhibits enhanced blocking activities compared to RMT2-14 .

These antibodies were selected based on their reactivity to mouse TIM-2-transfected cells but not to parental cells, ensuring specificity for the target protein .

How is RMT2 antibody generated for research applications?

The generation of RMT2 antibodies follows a well-established hybridoma technology process. Specifically, RMT2 antibodies were generated by immunizing Sprague Dawley rats with TIM-2-Ig, a fusion protein consisting of the extracellular domain (amino acids 1-230 of mouse TIM-2) and the Fc portion of mouse IgG2a. This immunogen was administered emulsified in complete Freund's adjuvant (CFA) .

Three days after the final immunization, lymph node cells from the immunized rats were harvested and fused with P3U1 myeloma cells. Following hypoxanthine-aminopterin-thymidine selection, hybridomas producing anti-TIM-2 monoclonal antibodies were selected based on their specific reactivity to mouse TIM-2-transfected cells, but not to parental cells, as determined by flow cytometry. The positive hybridomas were subsequently cloned by limiting dilution to ensure monoclonality . For purification, the antibodies were extracted from ascites of SCID mice using octanoic acid and ammonium sulfate precipitation, with final purity verified by SDS-PAGE analysis .

How is RMT2 antibody used in immunological research?

RMT2 antibodies serve as valuable tools in immunological research, particularly in studies investigating the functional roles of TIM-2 in immune regulation. Key applications include:

• Blocking experiments: RMT2 antibodies are frequently used to block TIM-2 signaling in vitro and in vivo, enabling researchers to assess the consequences of TIM-2 pathway disruption. In collagen-induced arthritis (CIA) models, administration of anti-TIM-2 mAbs during the early phase has been shown to significantly exacerbate disease development, indicating TIM-2's role in modulating autoimmune responses .

• Flow cytometry: These antibodies are employed to detect and quantify TIM-2 expression on various cell populations, including B cells, activated T cells (particularly Th2 cells), epithelial cells, and oligodendrocytes .

• Mechanistic studies: RMT2 antibodies have been instrumental in elucidating the mechanisms of TIM-2 function in different immune contexts, revealing its involvement in both T and B cell responses. Studies have demonstrated that anti-TIM-2 mAbs can enhance proliferation and antibody production of activated B cells in vitro .

• Autoimmune disease models: The application of RMT2 antibodies in models like collagen-induced arthritis has provided insights into how TIM-2 signaling contributes to autoimmune pathogenesis, showing that its influence on B cell responses may be more significant than its effects on T cell differentiation in certain disease contexts .

What methodological considerations are important when using RMT2 antibody in collagen-induced arthritis models?

When designing experiments using RMT2 antibodies in collagen-induced arthritis (CIA) models, researchers should consider several critical methodological aspects:

• Timing of administration: The timing of anti-TIM-2 mAb administration significantly impacts experimental outcomes. Research has demonstrated that early-phase administration (days 0-42 or days 0-17 post-immunization) significantly exacerbates CIA development, whereas late-phase administration (days 15-32) shows no significant effect. This temporal difference highlights the distinct roles of TIM-2 during different phases of disease progression .

• Dosing regimen: Typical experimental protocols involve intraperitoneal administration of 300 μg of anti-TIM-2 mAbs every three days. The specific schedule should be determined based on the phase being targeted (early or late) and the research question being addressed .

• Appropriate controls: Control groups should receive equivalent doses of isotype-matched control rat IgG (e.g., rat IgG2a for RMT2-14 and RMT2-25, rat IgG2b for RMT2-26) to account for potential non-specific effects of antibody administration .

• Assessment parameters:

  • Clinical scoring should be performed daily in a blinded manner

  • Swelling of all four paws should be graded from 0 to 4 (where 0 = no swelling; 1 = one inflamed digit; 2 = two inflamed digits; 3 = more than one digit and footpad inflamed; 4 = all digits and footpad inflamed)

  • Total scores should be calculated by summing the grades of all four paws (maximum score: 16)

  • Disease incidence should be reported as the percentage of mice showing paw swelling

• Immunological analyses: Comprehensive evaluation should include:

  • Assessment of antigen-specific T cell responses through proliferation assays

  • Measurement of cytokine production profiles

  • Determination of serum antibody levels using properly standardized ELISA

  • Analysis of TIM-2 expression on relevant cell populations by flow cytometry

How do different RMT2 antibody clones compare in their blocking efficiency?

Experimental evidence indicates significant differences in the blocking efficiency among the three primary RMT2 antibody clones:

• Comparative blocking potency: Both RMT2-25 and RMT2-26 demonstrate somewhat stronger blocking activities than RMT2-14 in functional assays, suggesting they may more effectively inhibit TIM-2 signaling . This difference should be considered when selecting a clone for blocking experiments, as it may influence the magnitude of observed effects.

• Epitope targeting: Although all three clones target TIM-2, they may recognize different epitopes within the extracellular domain, potentially explaining their varying blocking efficiencies. The specific epitope recognition patterns of these antibodies have not been fully characterized in the available literature .

• Applications based on blocking potential:

  • For experiments requiring moderate TIM-2 blockade, RMT2-14 may be preferred

  • When more complete inhibition of TIM-2 signaling is desired, RMT2-25 or RMT2-26 might be more appropriate

  • For dose-response studies examining the effects of varying degrees of TIM-2 inhibition, comparing multiple clones could provide valuable insights

When designing experiments, researchers should carefully consider these differences in blocking efficiency to select the most appropriate antibody clone for their specific research questions.

What is the role of TIM-2 in T cell regulation?

TIM-2 plays complex regulatory roles in T cell immunity, particularly in Th2 responses:

• Expression pattern: TIM-2 is preferentially expressed on Th2 cells but not on Th1 cells, suggesting a lineage-specific function in T helper cell differentiation and activity . This differentiated expression pattern indicates TIM-2's involvement in regulating type 2 immune responses.

• Negative regulation of Th2 responses: Multiple studies support TIM-2's role as a negative regulator of Th2 immune responses. Treatment with soluble TIM-2-Ig fusion protein (which blocks natural TIM-2 interactions) has been shown to induce T cell hyperproliferation and enhance production of Th2 cytokines . Similarly, in ovalbumin (OVA)-induced asthma models, TIM-2-Ig treatment exacerbated lung inflammation, increased eosinophil numbers in bronchial lavage, enhanced lymph node cell proliferation in response to OVA, and heightened production of Th2-type cytokines .

• Genetic evidence: TIM-2-deficient mice show exacerbated lung inflammation in OVA-induced asthma models, further supporting TIM-2's role as a critical negative regulator of Th2 immune responses .

• Signaling mechanisms: TIM-2 contains a conserved intracellular tyrosine phosphorylation motif involved in transmembrane signaling, suggesting it actively transduces signals that modulate T cell function rather than merely serving as a passive ligand-binding receptor .

• Interaction with Semaphorin 4A: TIM-2 functions as a receptor for Semaphorin 4A (Sema4A), which is expressed on activated macrophages, B cells, and dendritic cells. This interaction may represent one mechanism through which TIM-2 influences T cell activation and differentiation .

How does TIM-2 influence B cell function?

Research using RMT2 antibodies has revealed significant roles for TIM-2 in B cell biology:

• Expression on B cells: TIM-2 is expressed on splenic B cells and is further upregulated following stimulation with anti-immunoglobulin M (anti-IgM), anti-CD40, and interleukin-4 (IL-4) . This stimulation-dependent expression pattern suggests TIM-2 may be involved in B cell activation processes.

• Effects on B cell proliferation: Anti-TIM-2 mAbs enhance the proliferation of activated B cells in vitro, indicating that TIM-2 signaling may normally function to restrain B cell proliferation . This finding suggests TIM-2 could serve as a regulatory checkpoint preventing excessive B cell activation.

• Impact on antibody production: Treatment with anti-TIM-2 mAbs enhances antibody production by activated B cells in vitro. Additionally, in the collagen-induced arthritis model, anti-TIM-2 mAb administration significantly increases serum levels of anti-collagen antibodies . These findings suggest TIM-2 may regulate humoral immune responses by modulating B cell antibody secretion.

• Role in autoimmune pathology: The exacerbation of collagen-induced arthritis by anti-TIM-2 mAb treatment appears to be mediated primarily through enhanced B cell responses rather than effects on T cell differentiation. While anti-TIM-2 mAb treatment did not affect the development of Th1 or Th17 cells in draining lymph nodes, it significantly increased serum levels of anti-collagen antibodies, suggesting B cell-mediated effects are predominant in this context .

• Temporal significance: TIM-2's influence on B cell function appears particularly important during the early phase of immune responses, as evidenced by the observation that early-phase, but not late-phase, administration of anti-TIM-2 mAbs significantly exacerbated CIA development .

What is known about TIM-2 expression patterns across different cell types?

TIM-2 exhibits distinct expression patterns across multiple cell types, providing insights into its diverse physiological roles:

How should researchers interpret results from RMT2 antibody blocking versus genetic knockout studies?

When studying TIM-2 function, researchers should carefully consider potential discrepancies between antibody blocking and genetic knockout approaches:

• Temporal considerations: Antibody blocking with RMT2 provides temporal control over TIM-2 inhibition, allowing researchers to target specific phases of immune responses. In contrast, genetic knockouts eliminate TIM-2 function throughout development and in all expressing tissues simultaneously. This distinction is exemplified in CIA models, where early-phase, but not late-phase, administration of anti-TIM-2 mAbs significantly exacerbated disease development .

• Compensatory mechanisms: In genetic knockout models, compensatory upregulation of functionally related molecules may occur during development, potentially masking some phenotypes. Acute blockade with RMT2 antibodies may reveal functions that are obscured by compensatory mechanisms in knockout models.

• Differences in mechanism: Antibody blocking primarily inhibits extracellular interactions, while genetic knockout eliminates both ligand binding and potential intracellular signaling functions. Given that TIM-2 contains a conserved intracellular tyrosine phosphorylation motif involved in transmembrane signaling, these approaches may yield different results .

• Epitope-specific effects: Different RMT2 antibody clones may recognize distinct epitopes on TIM-2, potentially blocking some interactions while preserving others. This epitope-specific blockade may produce different outcomes compared to complete genetic ablation of TIM-2 .

• Reconciling conflicting results: When antibody blocking and genetic knockout studies yield contradictory results, researchers should consider:

  • Whether the antibody achieved complete blockade of all TIM-2 functions

  • If timing or dosage of antibody administration was optimal

  • Whether genetic compensation occurred in knockout models

  • If strain differences influenced experimental outcomes

What are the implications of dual-antibody therapy resistance for RMT2 antibody research?

Recent research on therapeutic monoclonal antibodies has highlighted important considerations for antibody escape that apply to RMT2 antibody research:

• Selection pressure and escape variants: Studies with other therapeutic antibodies, such as those targeting SARS-CoV-2, have demonstrated that selective pressure from monoclonal antibodies can drive the emergence of escape variants, particularly in immunocompromised individuals . This principle may extend to other antigen-antibody systems, including TIM-2 and RMT2 antibodies in certain experimental contexts.

• Dual-antibody approaches: Combining different RMT2 clones (e.g., RMT2-14 with RMT2-25 or RMT2-26) that recognize distinct epitopes might provide more complete TIM-2 blockade and reduce the probability of escape variants emerging in long-term studies .

• Target mutation consequences: If selective pressure from RMT2 antibodies drives mutations in TIM-2, these mutations might affect not only antibody binding but also natural ligand interactions. For example, SARS-CoV-2 escape from dual monoclonal antibody therapy occurred at the expense of ACE-2 binding capacity . Similarly, potential TIM-2 mutations might alter interactions with Semaphorin 4A or H-ferritin, changing the protein's normal function.

• Experimental design implications: For long-term in vivo studies using RMT2 antibodies, researchers should consider:

  • Monitoring for potential changes in TIM-2 expression or structure

  • Using multiple antibody clones targeting different epitopes

  • Incorporating periodic assessment of continued antibody binding

  • Considering the host's immune status when interpreting results

How can RMT2 antibody be applied in studies of autoimmune disease mechanisms?

RMT2 antibodies have proven particularly valuable for investigating autoimmune disease mechanisms, as evidenced by studies in collagen-induced arthritis (CIA):

• Revealing disease phase-specific roles: Administration of anti-TIM-2 mAbs during the early phase (days 0-42 or days 0-17 post-immunization), but not late phase (days 15-32), significantly exacerbated CIA development. This finding revealed that TIM-2's regulatory function is particularly critical during the initiation and establishment of autoimmune responses, rather than during the effector phase .

• Dissecting T cell versus B cell contributions: Anti-TIM-2 mAb treatment did not affect the development of Th1 or Th17 cells in the draining lymph nodes of CIA mice, but significantly increased serum levels of anti-collagen antibodies. This differential effect helps delineate the relative contributions of T cell-mediated versus B cell-mediated mechanisms in autoimmune pathology .

• Exploring regulatory mechanisms in different autoimmune contexts: While TIM-2 appears to primarily regulate B cell responses in CIA, its preferential expression on Th2 cells and regulatory role in Th2-mediated diseases like asthma suggest context-dependent functions. Comparing TIM-2's role across different autoimmune models could reveal how the same molecule can exert distinct regulatory effects depending on the immune environment .

• Investigating therapeutic implications: Understanding the mechanistic basis of TIM-2's regulatory functions in autoimmunity could inform therapeutic strategies. For instance, enhancing TIM-2 signaling during the early phase of autoimmune disease development might help restrain pathogenic B cell responses .

• Methodological approach: Researchers studying autoimmune mechanisms using RMT2 antibodies should:

  • Clearly define disease phases for intervention

  • Comprehensively assess both T and B cell responses

  • Measure autoantibody production using standardized assays

  • Consider potential differences between Th1-dominant versus Th2-dominant autoimmune conditions

What controls should be included in RMT2 antibody experiments?

Proper experimental controls are critical for accurately interpreting results from studies using RMT2 antibodies:

• Isotype controls: Experiments should include appropriate isotype-matched control antibodies:

  • Rat IgG2a for RMT2-14 and RMT2-25

  • Rat IgG2b for RMT2-26
    These controls account for potential non-specific effects of antibody binding or Fc receptor interactions .

• Antigen specificity controls: When using RMT2 antibodies for flow cytometry or functional assays, include:

  • TIM-2-negative cell lines as negative controls

  • TIM-2-transfected cell lines as positive controls

  • Blocking with unlabeled antibody to confirm specific binding

• Functional validation controls: When studying TIM-2 function:

  • Compare multiple RMT2 clones with varying blocking potencies (RMT2-25 and RMT2-26 show stronger blocking than RMT2-14)

  • Include TIM-2-Ig fusion protein as an alternative approach to block TIM-2/ligand interactions

  • When possible, compare results with TIM-2 knockout models

• Experimental timing controls: For in vivo studies:

  • Include groups receiving antibody treatment during different phases of the response

  • Implement appropriate vehicle controls matched to antibody formulation

  • Consider including time-matched sampling for all analyses

• Antigen-specific response controls: When assessing immune responses:

  • Include unrelated antigens (e.g., OVA in CIA studies) to distinguish antigen-specific from generalized effects

  • Perform dose-response analyses with varying antigen concentrations

  • Include appropriate positive controls for cell activation

How should RMT2 antibody dosing be determined for in vivo experiments?

Establishing appropriate dosing regimens for in vivo experiments with RMT2 antibodies requires careful consideration:

• Established effective doses: Previous studies have demonstrated efficacy with intraperitoneal administration of 300 μg of anti-TIM-2 mAbs per dose in mouse models. This dosing has been shown to effectively modulate TIM-2 function in vivo, as evidenced by significant effects on CIA development .

• Administration schedule: For sustained TIM-2 blockade, antibody administration every three days has proven effective. Specific schedules that have demonstrated biological effects include:

  • Days 0, 2, 5, 8, 11, 14, and 17 for targeting early disease phase

  • Days 15, 17, 20, 23, 26, 29, and 32 for targeting late disease phase

• Phase-specific considerations: When designing dosing regimens, researchers should carefully consider which phase of the immune response they wish to target. Early-phase (days 0-17) and late-phase (days 15-32) administration of anti-TIM-2 mAbs have shown significantly different outcomes in CIA models .

• Dose-response relationships: While established protocols typically use 300 μg per dose, researchers may consider performing dose-response studies (e.g., 100 μg, 300 μg, 500 μg) to determine optimal dosing for their specific experimental system and research questions.

• Monitoring considerations: When implementing RMT2 antibody dosing regimens, researchers should:

  • Monitor for potential anti-rat antibody responses with prolonged treatment

  • Consider how the pharmacokinetics of different RMT2 clones might influence dosing intervals

  • Assess target occupancy when feasible to confirm effective blockade

  • Evaluate potential systemic effects of sustained TIM-2 blockade

What techniques can be used to evaluate the efficacy of RMT2 antibody in blocking TIM-2 function?

Researchers can employ several approaches to assess the effectiveness of RMT2 antibodies in blocking TIM-2 function:

• In vitro functional assays:

  • B cell proliferation assays: Anti-TIM-2 mAbs enhance proliferation of activated B cells, providing a functional readout of blocking efficacy

  • Antibody production assays: Measure antibody secretion from B cells treated with anti-TIM-2 mAbs

  • T cell cytokine production: In Th2 contexts, effective TIM-2 blockade should enhance Th2 cytokine production

• Flow cytometric approaches:

  • Competition assays: Pre-incubation with unlabeled RMT2 antibody should block subsequent binding of fluorescently-labeled RMT2 antibody

  • Ligand binding inhibition: Assess whether RMT2 antibody treatment blocks binding of labeled TIM-2 ligands (e.g., Semaphorin 4A, H-ferritin)

  • Internalization assays: Evaluate whether antibody binding leads to receptor internalization, which may indicate functional engagement

• Biochemical validation:

  • Immunoprecipitation: Confirm RMT2 antibody can pull down TIM-2 from expressing cells

  • Western blotting: Detect TIM-2 protein in immunoprecipitates or cell lysates

  • Phosphorylation assays: Since TIM-2 contains a tyrosine phosphorylation motif, assess whether RMT2 antibody binding alters TIM-2 phosphorylation status

• In vivo validation markers:

  • Serum antibody levels: In CIA models, effective TIM-2 blockade significantly increases anti-collagen antibody titers

  • Disease parameters: Clinical scoring of arthritis severity provides a functional readout of blocking efficacy

  • Cellular responses: Assessment of antigen-specific proliferation in draining lymph nodes

• Comparison across antibody clones:

  • Side-by-side comparison of RMT2-14, RMT2-25, and RMT2-26 can provide insights into relative blocking potencies

  • Differential effects observed with these clones should correlate with their known blocking strengths (RMT2-25 and RMT2-26 > RMT2-14)